Alena Kreychman
Baystate Medical Center, USA
Scientific Tracks Abstracts: J Cancer Sci Ther
Xofigo is an alpha-particle emitting radio isotope radium-223 dichloride. The drug mimics calcium and forms complexes with the bone mineral at sites of bone metastatses. It then emits alpha particles, causing the destruction of DNA in nearby cells, resulting in cancer cell death in the bone. Xofigo is the only therapeutic radiopharmaceutical in treatment of bony metastasis. When it comes to unsealed sources of radiation, this is the first one that has shown significant survival benefits. That is a historical event in the radiotherapies. There are also secondary benefits, including delaying time to first skeletal-related event. It is also the first alpha emitter that has been FDA approved. The critical feature of an alpha emitter is that it is a much more powerful particle, which travels a shorter distance while hitting the cancer cells harder and avoding the healthy cells, so the complication rates are decreased. Because of those reasons, Xofigo is really making a huge impact in the history of oncologic interventions.
Alena Kreychman is a radiologist at Baystate Medical Center and Radiology and Imaging, Inc. She is an Assistant Professor of Radiology at UMMS-Baystate, an Adjunct Assistant Professor of Radiology at Tufts University Medical School, and serves as visiting faculty at Harvard Medical School. She has given multiple grand rounds presentations locally, regionally, and nationally. Dr. Kreychman is frequently involved in research and was the primary investigator on four out of six IRB submissions from the Radiology Department within the past few years. She is an active member of the Baystate Organization Women Advancing and Achieving in Medicine (WAAM), and serves as Administrative Officer for the organization.
Cancer Science & Therapy received 3968 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 